| Literature DB >> 35163584 |
Igor Smojver1, Ivan Katalinić1, Roko Bjelica1,2, Dragana Gabrić2, Vid Matišić1, Vilim Molnar1, Dragan Primorac1,3,4,5,6,7,8,9,10.
Abstract
Application of mesenchymal stem cells (MSC) in regenerative therapeutic procedures is becoming an increasingly important topic in medicine. Since the first isolation of dental tissue-derived MSC, there has been an intense investigation on the characteristics and potentials of these cells in regenerative dentistry. Their multidifferentiation potential, self-renewal capacity, and easy accessibility give them a key role in stem cell-based therapy. So far, several different dental stem cell types have been discovered and their potential usage is found in most of the major dental medicine branches. These cells are also researched in multiple fields of medicine for the treatment of degenerative and inflammatory diseases. In this review, we summarized dental MSC sources and analyzed their treatment modalities with particular emphasis on temporomandibular joint osteoarthritis (TMJ OA).Entities:
Keywords: dental stem cells; mesenchymal stem cells; regenerative dentistry; regenerative endodontic treatment; temporomandibular joint disorders; tissue regeneration
Mesh:
Year: 2022 PMID: 35163584 PMCID: PMC8836082 DOI: 10.3390/ijms23031662
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Specific characteristics of different dental tissue-derived MSCs.
| Surface Antigens | Immunomodulatory Functions | Differentiation Potential | |
|---|---|---|---|
| Dental pulp stem cells (DPSC) | CD13, CD29, CD44, CD59, CD73, CD90, CD105, CD146, STRO-1 | release of transforming growth factor beta (TGF-β), prostaglandin E2 (PGE2) and interleukin-6 (IL-6); stimulation of T cells to release TGF-β | odontogenic, angiogenic, myogenic, adipogenic, osteogenic, and neurogenic |
| Stem cells from exfoliated deciduous teeth (SHED) | CD166, CD146, CD90, CD73, CD29 | repression of T helper 17 (Th17) lymphocytes; upregulation of CD206+ M2 macrophages | osteogenic, chondrogenic, adipogenic, odontogenic, angiogenic, and neurogenic |
| Stem cells from apical papilla (SCAP) | CD146, CD90, CD44, CD24, STRO-1 | suppression of T cell proliferation | osteogenic, odontogenic, neurogenic, adipogenic, and chondrogenic |
| Periodontal ligament stem cells (PDLSC) | CD105, CD73, CD44, CD29, CD10 | suppression of IL-1β production; suppression of peripheral blood mononuclear cells (PBMNCs) proliferation; downregulation of tumor necrosis factor-α (TNF-α) | chondrogenic, osteogenic, neurogenic, and adipogenic |
| Alveolar bone-derived mesenchymal stem cells (ABMSC) | CD73, CD90, CD105, STRO-1 | immunosuppressive effects on monocyte and T cell activation; secretion of interleukin (IL)-6 and monocyte chemoattractant protein (MCP)-1 | osteogenic and adipogenic |
| Gingival-derived mesenchymal stem cells (GMSC) | CD73, CD90, CD105 | upregulation of interleukin-10 (IL-10); suppression of mast cell degranulation; suppression of PBMNCs proliferation | chondrogenic, osteogenic, adipogenic, angiogenic, and neurogenic |
| Dental follicle stem cells (DFSC) | CD13, CD29, CD44, CD49d, CD56, CD59, CD90, CD105, CD106, CD166, STRO-1 | upregulation of TGF-β and IL-6 secretion; suppression of PBMNCs proliferation | odontogenic, cementogenic, and osteogenic |
| Tooth germ stem cells (TGSC) | CD73, CD90, CD105, CD166 | not investigated | osteogenic, adipogenic, chondrogenic, and neurogenic |
Figure 1Schematic representation of three different regenerative endodontic treatment (RET) strategies. Cell-free strategy (CF) mainly relies on induced bleeding from periapical tissues, bringing different cells like mesenchymal stem cells (MSCs), immunoglobulins, cytokines, and growth factors (GFs) into a root canal. Cell-based strategy (CB) relies on the interplay between three main factors of the “tissue engineering triad”: stem cells, signaling molecules, and scaffolds. Exosome strategy presents an intermediate approach using conditioned medium (CM) of MSCs. Created with BioRender.com.